COMMUNIQUÉS West-GlobeNewswire
-
Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 2017
27/07/2017 - 14:30 -
Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year
27/07/2017 - 13:00 -
Arix Bioscience co-leads $29 million Series A financing for PreciThera, Inc.
27/07/2017 - 13:00 -
RECORDATI: VERY GOOD RESULTS IN THE FIRST HALF 2017. CONTINUED GROWTH IN SALES +10.7%, OPERATING INCOME +19.4%, NET INCOME +19.8%
27/07/2017 - 11:23 -
William Demant Holding A/S: Major shareholder announcement concerning Canada Pension Plan Investment Board
27/07/2017 - 10:31 -
Bavarian Nordic Announces Additional Details Regarding the Issue of Shares to Johnson & Johnson Innovation - JJDC, Inc.
27/07/2017 - 08:05 -
Bavarian Nordic Announces Agreement with Janssen for the Development of Vaccine Regimens against HIV-1 and Hepatitis B
27/07/2017 - 08:00 -
Financière de Tubize SA: 2017 half-year financial report
27/07/2017 - 08:00 -
Financière de Tubize SA: Rapport financier semestriel 2017
27/07/2017 - 08:00 -
Nestlé reports half-year results for 2017
27/07/2017 - 07:19 -
VALNEVA et Emergent BioSolutions joignent leurs forces pour développer un vaccin contre le virus Zika
26/07/2017 - 22:15 -
VALNEVA and Emergent BioSolutions Join Forces to Develop a Vaccine against the Zika Virus
26/07/2017 - 22:15 -
Oriola Corporation - Repurchase of own shares on 26 July 2017
26/07/2017 - 17:47 -
Navamedic ASA: Presentation of second quarter figures
26/07/2017 - 14:52 -
Apricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call
26/07/2017 - 13:00 -
Gap In Perceived and Actual Rates Of Prescription Stimulant Misuse, Abuse and Diversion Found Among College Students
26/07/2017 - 13:00 -
Midatech Pharma Plc: Completion of pre-clinical liver cancer programme
26/07/2017 - 13:00 -
Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment
26/07/2017 - 08:00 -
ABLYNX RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP
26/07/2017 - 07:00
Pages